These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 11951839)
41. K65R, TAMs and tenofovir. Miller MD AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738 [TBL] [Abstract][Full Text] [Related]
42. FDA notifications. FDA's tentative approval for generic Tenofovir. AIDS Alert; 2008 Jan; 23(1):11-2. PubMed ID: 18572475 [No Abstract] [Full Text] [Related]
43. Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'. Matthews GV; Dore GJ AIDS; 2007 Mar; 21(6):777-8. PubMed ID: 17413705 [No Abstract] [Full Text] [Related]
45. Prevention: new approach will test tenofovir for persons at high risk. James JS AIDS Treat News; 2002 Nov; (385):4. PubMed ID: 12492041 [No Abstract] [Full Text] [Related]
46. The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1. McColl DJ; Miller MD J Antimicrob Chemother; 2003 Feb; 51(2):219-23. PubMed ID: 12562684 [No Abstract] [Full Text] [Related]
47. Anti-HIV agents. The puzzle of virologic failure with tenofovir. TreatmentUpdate; 2004; 16(3):4. PubMed ID: 17216834 [No Abstract] [Full Text] [Related]
48. Effect of tenofovir on renal glomerular and tubular function. Fux CA; Christen A; Zgraggen S; Mohaupt MG; Furrer H AIDS; 2007 Jul; 21(11):1483-5. PubMed ID: 17589197 [TBL] [Abstract][Full Text] [Related]
49. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC. Feinberg J AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373 [No Abstract] [Full Text] [Related]
51. [96-week treatment outcome confirms long term efficacy of tenofovir DF]. Dtsch Med Wochenschr; 2003 May; 128(19):1074-5. PubMed ID: 12774796 [No Abstract] [Full Text] [Related]
52. Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility. Liu Y; Wang CM; Cheng J; Liang ZL; Zhong YW; Ren XQ; Xu ZH; Zoulim F; Xu DP Chin Med J (Engl); 2009 Jul; 122(13):1585-6. PubMed ID: 19719953 [No Abstract] [Full Text] [Related]
53. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. Miller MD; Margot N; Lu B; Zhong L; Chen SS; Cheng A; Wulfsohn M J Infect Dis; 2004 Mar; 189(5):837-46. PubMed ID: 14976601 [TBL] [Abstract][Full Text] [Related]
54. Potency of tenofovir in chronic hepatitis B: mono or combination therapy? Reijnders JG; Janssen HL J Hepatol; 2008 Mar; 48(3):383-6. PubMed ID: 18191272 [No Abstract] [Full Text] [Related]